Top Page
New China Life Insurance Co., Ltd. Class H
(1336)
New China Life Insurance Co., Ltd. Class H (1336) vs. iShares MSCI Hong Kong ETF (EWH)
New China Life Insurance Co., Ltd. Class H Business Overview & Revenue Model
New China Life Insurance Co., Ltd. Class H Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 116.92B | 128.86B | 70.10B | 106.89B | 222.00B | 206.28B |
| Gross Profit | 116.92B | 128.86B | 70.10B | 96.72B | 207.41B | 188.45B |
| EBITDA | 61.28B | 29.88B | 67.84B | 99.86B | 17.29B | 17.01B |
| Net Income | 29.95B | 26.23B | 8.71B | 21.50B | 14.95B | 14.29B |
Balance Sheet | ||||||
| Total Assets | 1.78T | 1.69T | 1.40T | 1.26T | 1.13T | 1.00T |
| Cash, Cash Equivalents and Short-Term Investments | 32.58B | 38.46B | 21.81B | 393.24B | 418.90B | 439.70B |
| Total Debt | 20.91B | 31.10B | 21.02B | 10.86B | 11.04B | 11.06B |
| Total Liabilities | 1.69T | 1.60T | 1.30T | 1.15T | 1.02T | 902.70B |
| Stockholders Equity | 83.41B | 96.24B | 105.07B | 102.88B | 108.50B | 101.67B |
Cash Flow | ||||||
| Free Cash Flow | 65.44B | 95.19B | 89.46B | 87.60B | 70.59B | 64.14B |
| Operating Cash Flow | 58.72B | 96.29B | 91.55B | 89.39B | 73.85B | 67.18B |
| Investing Cash Flow | -131.48B | -141.77B | -156.65B | -90.47B | -106.53B | -67.73B |
| Financing Cash Flow | 44.14B | 62.03B | 69.29B | 2.84B | 35.24B | 1.97B |
New China Life Insurance Co., Ltd. Class H Technical Analysis
New China Life Insurance Co., Ltd. Class H Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
83 Outperform | HK$260.73B | 6.13 | 34.37% | 5.24% | 49.90% | 203.77% | |
80 Outperform | HK$1.42T | 8.32 | 28.10% | 3.42% | 17.69% | 126.41% | |
79 Outperform | HK$459.78B | 6.69 | 18.41% | 3.28% | 15.08% | 23.13% | |
78 Outperform | HK$1.34T | 8.64 | 14.53% | 4.25% | 10.20% | 19.74% | |
72 Outperform | HK$946.50B | 20.68 | 15.16% | 2.16% | 5.65% | 30.47% | |
71 Outperform | HK$74.76B | 6.26 | 11.12% | 3.22% | 2.54% | 17.80% | |
68 Neutral | $18.00B | 11.42 | 9.92% | 3.81% | 9.73% | 1.22% |
New China Life Insurance Co., Ltd. Class H Corporate Events
New China Life Insurance Company Ltd., a leading Chinese life insurer listed in Hong Kong, focuses on providing life insurance and related financial protection services across mainland China and Hong Kong.
The company has obtained approval from China’s National Financial Regulatory Administration for amendments to its Articles of Association, including the formal abolition of its board of supervisors following shareholder approval at its third extraordinary general meeting in 2025. With the amended Articles now in effect, the Rules of Procedures of the Board of Supervisors have been cancelled and four supervisors—Liu Debin, Yu Jiannan, Wang Zhongzhu and Liu Chongsong—have stepped down, all confirming they have no disagreements with the company or issues requiring shareholder attention. The move reflects an adjustment to New China Life’s corporate governance structure in line with updated regulations and its own governance practices, and formalizes a new oversight framework under the revised Articles of Association.
The most recent analyst rating on (HK:1336) stock is a Buy with a HK$72.00 price target. To see the full list of analyst forecasts on New China Life Insurance Co., Ltd. Class H stock, see the HK:1336 Stock Forecast page.
New China Life Insurance Company Ltd. reported unaudited accumulated gross premium income of RMB195.9 billion for the full year 2025, representing a 15% year-on-year increase, highlighting solid top-line growth in its core life insurance business. During the year, the company pursued a broad transformation agenda aimed at boosting market competitiveness, including strengthening basic management, building a service ecosystem, promoting product innovation, developing its sales force, enhancing operations with technology, better coordinating assets and liabilities, and cultivating its brand culture, measures that are intended to provide sustained internal momentum for high-quality growth and may further reinforce its positioning in China’s competitive insurance market, though investors are cautioned that the figures have not yet been audited.
The most recent analyst rating on (HK:1336) stock is a Buy with a HK$59.00 price target. To see the full list of analyst forecasts on New China Life Insurance Co., Ltd. Class H stock, see the HK:1336 Stock Forecast page.
New China Life Insurance Company Ltd. has formed the ninth session of its board of directors, comprising 10 members including executive, non-executive and independent non-executive directors, and has elected executive director Yang Yucheng as chairman with immediate effect from the board’s first meeting on 24 December 2025. The company has also reconfigured its key board committees—covering strategy and ESG, investment and asset-liability management, audit and related-party transactions, nomination and remuneration, and risk management and consumer rights protection—assigning chairmanships and memberships to directors based on their roles and expertise, while noting that appointments involving incoming independent non-executive director Sau Fun Cheung will only take effect once her regulatory approval is obtained, with existing independent director Ma Yiu Tim continuing to serve in the interim, ensuring continuity of governance and oversight.
The most recent analyst rating on (HK:1336) stock is a Buy with a HK$60.00 price target. To see the full list of analyst forecasts on New China Life Insurance Co., Ltd. Class H stock, see the HK:1336 Stock Forecast page.
New China Life Insurance Co., Ltd. has announced the current composition of its board of directors, confirming Yang Yucheng as chairman and executive director, alongside one other executive director, four non-executive directors and four independent non-executive directors. The insurer has also detailed the membership and chairmanship of its five key board committees covering strategy and ESG, investment and asset-liability management, audit and related-party transactions, nomination and remuneration, and risk management and consumer rights protection. The appointment of Sau Fun Cheung as an independent non-executive director and as a member of several board committees will take effect once ratified by regulators, with incumbent independent non-executive director Ma Yiu Tim continuing to serve in the interim, indicating a controlled and compliant transition in the company’s governance framework.
The most recent analyst rating on (HK:1336) stock is a Buy with a HK$60.00 price target. To see the full list of analyst forecasts on New China Life Insurance Co., Ltd. Class H stock, see the HK:1336 Stock Forecast page.
New China Life Insurance Company Ltd. secured shareholder approval at its fourth extraordinary general meeting of 2025 to issue domestic undated capital bonds, a move that will bolster its capital base and provide additional long-term funding flexibility. At the same meeting, shareholders overwhelmingly backed amendments to the company’s administrative measures on related-party transactions, reinforcing its governance framework and compliance with regulatory and listing requirements, with more than half of the company’s share capital represented and all resolutions passing with near-unanimous support.
The most recent analyst rating on (HK:1336) stock is a Buy with a HK$60.00 price target. To see the full list of analyst forecasts on New China Life Insurance Co., Ltd. Class H stock, see the HK:1336 Stock Forecast page.
New China Life Insurance Co., Ltd. announced a 16% year-on-year increase in its accumulated gross premium income, reaching RMB188,850.31 million for the period between January and November 2025. The company is committed to strengthening its insurance business and investment capabilities, focusing on structural optimization and quality improvement to enhance sustainable development competitiveness. The reported premium income is unaudited, and investors are advised to exercise caution.
The most recent analyst rating on (HK:1336) stock is a Buy with a HK$60.00 price target. To see the full list of analyst forecasts on New China Life Insurance Co., Ltd. Class H stock, see the HK:1336 Stock Forecast page.
New China Life Insurance Co., Ltd. has announced its fourth extraordinary general meeting scheduled for December 24, 2025, in Beijing. Key agenda items include the issuance of domestic undated capital bonds and amendments to administrative measures on related party transactions. Additionally, the meeting will address the election and re-election of directors for the ninth session of the board, which could impact the company’s governance and strategic direction.
The most recent analyst rating on (HK:1336) stock is a Buy with a HK$60.00 price target. To see the full list of analyst forecasts on New China Life Insurance Co., Ltd. Class H stock, see the HK:1336 Stock Forecast page.
New China Life Insurance Co., Ltd. announced the resignation of Mr. MA Yiu Tim from his role as an independent non-executive director after serving for six consecutive years. His resignation also includes stepping down from his positions in the Nomination and Remuneration Committee and the Risk Management and Consumer Rights Protection Committee. The company will maintain his directorship responsibilities until a new independent non-executive director is elected and approved by regulatory authorities. The board expressed gratitude for Mr. MA Yiu Tim’s contributions during his tenure.
The most recent analyst rating on (HK:1336) stock is a Buy with a HK$60.00 price target. To see the full list of analyst forecasts on New China Life Insurance Co., Ltd. Class H stock, see the HK:1336 Stock Forecast page.
New China Life Insurance Co., Ltd. has announced the nomination of candidates for the ninth session of its Board of Directors, as the current board’s term is nearing its end. The nominations include both executive and non-executive directors, with a particular focus on diversity and independence, as exemplified by the nomination of Ms. Sau Fun Cheung as an independent non-executive director. Her appointment is pending regulatory approval, and the company emphasizes her qualifications and alignment with its board diversity policy, indicating a strategic move to strengthen governance and enhance shareholder value.
The most recent analyst rating on (HK:1336) stock is a Buy with a HK$60.00 price target. To see the full list of analyst forecasts on New China Life Insurance Co., Ltd. Class H stock, see the HK:1336 Stock Forecast page.
New China Life Insurance Co., Ltd. reported an accumulated gross premium income of RMB181,973.02 million for the period from January to October 2025, marking a 17% increase year-on-year. The company is committed to high-quality development through systematic reforms and efforts across various dimensions, including products, distribution channels, and technology, aiming for both volume and value enhancement.
The most recent analyst rating on (HK:1336) stock is a Sell with a HK$37.90 price target. To see the full list of analyst forecasts on New China Life Insurance Co., Ltd. Class H stock, see the HK:1336 Stock Forecast page.
New China Life Insurance Co., Ltd. announced an update to its interim dividend for the six months ending June 30, 2025, declaring a dividend of RMB 0.67 per share. The update includes details on the default currency, exchange rate, and withholding tax for the dividend, which will be paid in HKD. The ex-dividend date is set for November 13, 2025, with payment scheduled for December 12, 2025. The announcement outlines the withholding tax rates applicable to non-resident shareholders based on their domicile’s tax treaty with China, impacting the net dividend received by these stakeholders.
The most recent analyst rating on (HK:1336) stock is a Buy with a HK$65.00 price target. To see the full list of analyst forecasts on New China Life Insurance Co., Ltd. Class H stock, see the HK:1336 Stock Forecast page.
New China Life Insurance Co., Ltd. recently held its third extraordinary general meeting of 2025, where shareholders approved the Interim Profit Distribution Plan for the year. The meeting, which complied with relevant legal and regulatory requirements, saw significant shareholder participation, with a resolution passed to distribute interim dividends, reflecting the company’s commitment to returning value to its shareholders.
The most recent analyst rating on (HK:1336) stock is a Buy with a HK$65.00 price target. To see the full list of analyst forecasts on New China Life Insurance Co., Ltd. Class H stock, see the HK:1336 Stock Forecast page.